112 related articles for article (PubMed ID: 1394243)
1. Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers.
Brion N; Kollenbach K; Marion MH; Grégoire A; Advenier C; Pays M
Clin Neuropharmacol; 1992 Jun; 15(3):229-35. PubMed ID: 1394243
[TBL] [Abstract][Full Text] [Related]
2. Circadian phase dependent pharmacokinetics of L-dopa, its main metabolites (3-OMD, HVA, DOPAC) and carbidopa in rats.
Andre MH; Grignon S; Bruguerolle B
Fundam Clin Pharmacol; 1996; 10(4):350-5. PubMed ID: 8871134
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection.
Sagar KA; Smyth MR
Analyst; 2000 Mar; 125(3):439-45. PubMed ID: 10829343
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
Schneider F; Erisson L; Beygi H; Bradbury M; Cohen-Barak O; Grachev ID; Guzy S; Loupe PS; Levi M; McDonald M; Savola JM; Papapetropoulos S; Tracewell WG; Velinova M; Spiegelstein O
Br J Clin Pharmacol; 2018 Oct; 84(10):2422-2432. PubMed ID: 29959802
[TBL] [Abstract][Full Text] [Related]
5. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
[TBL] [Abstract][Full Text] [Related]
6. The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle.
Deleu D; Sarre S; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1993 Dec; 348(6):576-81. PubMed ID: 8133901
[TBL] [Abstract][Full Text] [Related]
7. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
[TBL] [Abstract][Full Text] [Related]
8. The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study.
Deleu D; Sarre S; Ebinger G; Michotte Y
J Pharmacol Exp Ther; 1995 Jun; 273(3):1323-31. PubMed ID: 7791104
[TBL] [Abstract][Full Text] [Related]
9. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):180-189. PubMed ID: 32416054
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
[TBL] [Abstract][Full Text] [Related]
11. Caffeic acid improves the bioavailability of L-dopa in rabbit plasma.
Wang LH; Hsu KY; Uang YS; Hsu FL; Yang LM; Lin SJ
Phytother Res; 2010 Jun; 24(6):852-8. PubMed ID: 19941381
[TBL] [Abstract][Full Text] [Related]
12. Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
Bugamelli F; Marcheselli C; Barba E; Raggi MA
J Pharm Biomed Anal; 2011 Feb; 54(3):562-7. PubMed ID: 21035976
[TBL] [Abstract][Full Text] [Related]
13. Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment.
Rose S; Jenner P; Marsden CD
J Pharm Pharmacol; 1991 May; 43(5):325-30. PubMed ID: 1680174
[TBL] [Abstract][Full Text] [Related]
14. Effect of catechin and commercial preparation of green tea essence on the pharmacokinetics of l-dopa in rabbits.
Lin SJ; Tai L; Huang YJ; Uang YS; Ho Y; Hsu KY; Wang LH
Biomed Chromatogr; 2021 Dec; 35(12):e5227. PubMed ID: 34388856
[TBL] [Abstract][Full Text] [Related]
15. Chronic administration does not alter the pharmacokinetic profile of L-dopa in the rat.
Rose S; Jenner P; Marsden CD
J Pharm Pharmacol; 1993 Aug; 45(8):725-30. PubMed ID: 7901371
[TBL] [Abstract][Full Text] [Related]
16. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
Rose S; Jenner P; Marsden CD
Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration does not alter the accumulation of L-dopa into muscle.
Rose S; Jenner P; Marsden CD
Mov Disord; 1994 Mar; 9(2):167-72. PubMed ID: 8196677
[TBL] [Abstract][Full Text] [Related]
18. Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation.
Kashihara Y; Terao Y; Yoda K; Hirota T; Kubota T; Kimura M; Matsuki S; Hirakawa M; Irie S; Ieiri I
Eur J Clin Pharmacol; 2019 Mar; 75(3):351-361. PubMed ID: 30382297
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
Hsu A; Yao HM; Gupta S; Modi NB
J Clin Pharmacol; 2015 Sep; 55(9):995-1003. PubMed ID: 25855267
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
